Intraperitoneal treatment of a synthetic peptide AWRK6, a candidate agonist of GLP-1, can improve hepatic steatosis, glucose metabolism, and obesity in high energy diet (HED)-induced MAFLD mice, via modulating phosphoinositide 3-kinase (PI3K)/Protein kinase B (AKT)/AMP-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) signaling pathway [52]. The gene discussed is AKT1; the disease is obesity disorder.